<?xml version="1.0" encoding="UTF-8"?>
<p>The increased investments in NID research in Europe and globally have generated an increasing number of candidate products. The product pipeline has more than doubled in size over the last decade, and currently comprises more than 167 candidates for new drugs, vaccines and diagnostics 
 <xref rid="bb0065" ref-type="bibr">[13]</xref>.
</p>
